Targeting the mTOR/4E-BP pathway in endometrial cancer

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7518-7528

  Korets, Sharmilee Bansal ^a   Czok, Sarah ^a   Blank, Stephanie V ^a   Curtin, John P ^a   Schneider, Robert J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BEVACIZUMAB; BKM 120; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ESTROGEN; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MK 2206; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE LKB1; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN C; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; XL 147;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG TARGETING; DYSLIPIDEMIA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FATIGUE; HUMAN; INFECTION; MUCOSA INFLAMMATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84055176558     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1664     Document Type: Review

References (81)

1. American Cancer Society [homepage on the Internet]. Cancer Facts and Figures 2010. Available from: http://www.cancer.org/Research/CancerFactsFigures/ CancerFactsFigures/cancer-facts-and-figures-2010.
2. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111:436-47. (Pubitemid 351653438)
3. Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, et al. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Dis Model Mech 2010;3:181-93.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7. (Pubitemid 13194678)
5. Gadducci A, Tana R, Cosio S, Fanucchi A, Genazzani AR. Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol 2008;24:239-49. (Pubitemid 351891652)
6. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22: 2159-66. (Pubitemid 41095150)
7. Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ. Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother 2009;10:1939-51.
8. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-91. (Pubitemid 46630943)
9. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Contr 2009;16:8-13.
10. Hollander MC, BlumenthalGM,Dennis PA.PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
11. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
12. Stambolic V, Suzuki A, de la PompaJL, Brothers GM,Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39. (Pubitemid 28458022)
13. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999;9:125-8. (Pubitemid 29161437)
14. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 2001;61:4569-75. (Pubitemid 32685791)
15. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 2004;303:1179-81. (Pubitemid 38233580)
16. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000;60: 3605-11. (Pubitemid 30482183)
17. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92. (Pubitemid 43292562)
18. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-73. (Pubitemid 41713332)
19. Catasus L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008; 21:131-9. (Pubitemid 351172164)
20. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 2007;46:26-32.
21. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13:2004-8. (Pubitemid 37425212)
22. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25. (Pubitemid 43960587)
23. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90. (Pubitemid 37506046)
24. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008;68:759-66. (Pubitemid 351206752)
25. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 2008;14:2543-50.
26. Rutanen EM. Insulin-like growth factors in endometrial function. Gynecol Endocrinol 1998;12:399-406.
27. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001;61:589-93. (Pubitemid 32128619)
28. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 2006;12: 6373-8. (Pubitemid 44799707)
29. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004;90:2-8. (Pubitemid 38541717)
30. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011;332:1317-22.
31. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villén J, et al. Phosphoproteomic analysis identifies Grb10 as anmTORC1 substrate that negatively regulates insulin signaling. Science 2011;332:1322-6.
32. Zheng W, Baker HE, Mutter GL. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol 2004;92:1008-13. (Pubitemid 38251415)
33. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
34. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7:209-19.
35. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34. (Pubitemid 44286004)
36. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci 2009;34:620-7.
37. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101. (Pubitemid 40262113)
38. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4EBP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
39. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
40. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
41. Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001;7: 892-5. (Pubitemid 32708726)
42. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999;96:1563-8. (Pubitemid 29098491)
43. Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, et al. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol 2009;40: 1418-26.
44. No JH, Jeon YT, Park IA, Kang D, Kim JW, Park NH, et al. Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit 2009;15:BR301-5.
45. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63. (Pubitemid 29449212)
46. Pause A, Belsham GJ, Gingras AC, Donzé O, Lin TA, Lawrence JC Jr, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5¢-cap function. Nature 1994;371:762-7.
47. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, Gradi A, et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 2000;19:434-44. (Pubitemid 30072613)
48. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006;25:2781-91. (Pubitemid 43980385)
49. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007;2:e242.
50. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004;23: 3172-9.
51. Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, et al. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol 2011;137:463-9.
52. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009;135:933-41.
53. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009; 113:370-3.
54. Li X, Xiao L, Yang Y, Shen H, Zeng H, Wang Z. The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells. J Huazhong Univ Sci Technolog Med Sci 2008;28:340-2.
55. Milam MR, Soliman PT, Chung LH, Schmeler KM, Bassett RL Jr, Broaddus RR, et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer 2008;18:146-51.
56. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, et al. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Cancer Sci 2007;98:1881-8. (Pubitemid 350002193)
57. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
58. Wahl H, Daudi S, Kshirsagar M, Griffith K, Tan L, Rhode J, et al. Expression of metabolically targeted biomarkers in endometrial carcinoma. Gynecol Oncol 2010;116:21-7.
59. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009;115: 3887-96.
60. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 2010;126:1144-54.
61. Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102:292-9. (Pubitemid 44041641)
62. Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003;2:789-95.
63. An HJ, Cho NH, Yang HS, Kwak KB, Kim NK, Oh DY, et al. Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells. J Pathol 2007;212:161-9. (Pubitemid 46852094)
64. Erdemoglu E, Güney M, Giray SG, Take G, Mungan T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2009; 145:195-9.
65. McCampbell AS, Walker CL, Broaddus RR, Cook JD, Davies PJ. Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat. Lab Invest 2008;88:615-26. (Pubitemid 351733276)
66. Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, Slomovitz BM, et al. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 2007;196:247, e1-5.
67. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006;13[Suppl 1]:S15-24. (Pubitemid 46219245)
68. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242-56. (Pubitemid 43796082)
69. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95.
70. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47. (Pubitemid 41115390)
71. Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. J Clin Oncol 2006;24:3003.
72. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26:4319-25.
73. Colombo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 2007;25:5516.
74. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415-9.
75. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278-85.
76. Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment. Gynecol Oncol 2010;119:579-85.
77. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117:473-6.
78. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603. (Pubitemid 41540408)
79. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenicmTORpathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-61.
80. 1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 2011;54:1473-80.
81. Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000;89:1758-64.